Vigo

• Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (SchizOMICS) Recruiting
  2024-516768-28-00 6 2024-12-16 Schizophrenia
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy
• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i … Recruiting
  2023-504647-14-00 4 2024-09-02 Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
• Beta-Blockers in Takotsubo Syndrome: A Randomized Clinical Trial Recruiting
  2023-510213-25-01 6 2024-07-08 Takotsubo Syndrome (TT) is an acute cardiac condition
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 10 2024-05-22 systemic sclerosis associated interstitial lung disease
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting
  2023-507293-40-00 6 2024-04-11 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI (DEBATE) Recruiting
  2023-504340-34-01 6 2024-01-11 Coronary artery disease
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence … Recruiting
  2024-517666-41-00 5 2023-03-13 Prostate Cancer
• A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting
  2022-502917-27-00 5 2023-03-07 Migraine
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting
  2024-510656-13-00 5 2022-11-08 Migraine
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch … Recruiting
  2024-512382-13-00 5 2022-10-04 Migraine (with or without aura)
• EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Recruiting
  2023-507029-40-00 5 2022-05-09 Genetic carriers of dilated cardiomyopathy causing variants
• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo … Recruiting
  2023-508963-58-00 4 2022-01-31 Symptomatic hypertrophic cardiomyopathy (HCM)

Showing 73–96 of 214 trials